Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ten Approvals To Look Out For In Q4

Executive Summary

From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.


Related Content

Lilly, Novartis, Jazz and Ionis Take New Products To EMA
EU CHMP To Decide On New Drugs For Asthma, Diabetes, Hemophilia A, Ovarian Cancer – And Roche’s Ocrevus
Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000
New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Kite On Course For FDA Filing On Positive CAR-T Durability Data
Pivotal ALCANZA Trial Secures Adcetris' Position in Cutaneous Lymphoma
Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment
AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
Phase III Data Back Keryx's Plan To Expand Auryxia Market
Aeterna Zentaris tanks on FDA Macrilen rejection


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts